CA2110575A1 - Utilisation de derives de tetrahydrobenzazepine dans le traitement de l'hypertension et de la migraine spleniques - Google Patents
Utilisation de derives de tetrahydrobenzazepine dans le traitement de l'hypertension et de la migraine spleniquesInfo
- Publication number
- CA2110575A1 CA2110575A1 CA002110575A CA2110575A CA2110575A1 CA 2110575 A1 CA2110575 A1 CA 2110575A1 CA 002110575 A CA002110575 A CA 002110575A CA 2110575 A CA2110575 A CA 2110575A CA 2110575 A1 CA2110575 A1 CA 2110575A1
- Authority
- CA
- Canada
- Prior art keywords
- tetrahydro
- benzazepine
- compound
- hydroxy
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims description 29
- 208000019695 Migraine disease Diseases 0.000 title claims description 16
- 206010027599 migraine Diseases 0.000 title claims description 16
- 208000007232 portal hypertension Diseases 0.000 title claims description 16
- MZBVNYACSSGXID-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1-benzazepine Chemical class N1CCCCC2=CC=CC=C21 MZBVNYACSSGXID-UHFFFAOYSA-N 0.000 title abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000000556 agonist Substances 0.000 claims description 13
- 150000002431 hydrogen Chemical group 0.000 claims description 12
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 claims description 10
- 108091005479 5-HT2 receptors Proteins 0.000 claims description 10
- 239000000018 receptor agonist Substances 0.000 claims description 10
- 229940044601 receptor agonist Drugs 0.000 claims description 10
- AFCXBOVGVJGZSY-UHFFFAOYSA-N 8-methylsulfonyl-2,3,4,5-tetrahydro-1h-1-benzazepin-7-ol Chemical compound N1CCCCC2=C1C=C(S(=O)(=O)C)C(O)=C2 AFCXBOVGVJGZSY-UHFFFAOYSA-N 0.000 claims description 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000007800 oxidant agent Substances 0.000 claims description 3
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 claims description 3
- UUAJXCLXKIGVEO-UHFFFAOYSA-N 8-(trifluoromethylsulfonyl)-2,3,4,5-tetrahydro-1h-1-benzazepin-7-ol Chemical compound C1CCCNC2=C1C=C(O)C(S(=O)(=O)C(F)(F)F)=C2 UUAJXCLXKIGVEO-UHFFFAOYSA-N 0.000 claims description 2
- WCYXJUWAKAVQPX-UHFFFAOYSA-N 8-methylsulfinyl-2,3,4,5-tetrahydro-1h-1-benzazepin-7-ol Chemical compound N1CCCCC2=C1C=C(S(=O)C)C(O)=C2 WCYXJUWAKAVQPX-UHFFFAOYSA-N 0.000 claims description 2
- VJNXUPYYYSVGHS-UHFFFAOYSA-N 8-nitro-2,3,4,5-tetrahydro-1h-1-benzazepin-7-ol Chemical compound C1CCCNC2=C1C=C(O)C([N+]([O-])=O)=C2 VJNXUPYYYSVGHS-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000002140 halogenating effect Effects 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000000802 nitrating effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- AHXWNPZRTBMBJW-UHFFFAOYSA-N 1-(7-hydroxy-2,3,4,5-tetrahydro-1h-1-benzazepin-8-yl)ethanone Chemical compound N1CCCCC2=C1C=C(C(=O)C)C(O)=C2 AHXWNPZRTBMBJW-UHFFFAOYSA-N 0.000 claims 1
- FMBPGBHUWRTTKK-UHFFFAOYSA-N 6-bromo-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepine Chemical compound N1CCCCC2=C(Br)C(OC)=CC=C21 FMBPGBHUWRTTKK-UHFFFAOYSA-N 0.000 claims 1
- KLRQDJSMGYOZMZ-UHFFFAOYSA-N 7-bromo-2,3,4,5-tetrahydro-1h-1-benzazepin-8-ol Chemical compound N1CCCCC2=C1C=C(O)C(Br)=C2 KLRQDJSMGYOZMZ-UHFFFAOYSA-N 0.000 claims 1
- NYHWCJTZGDKRIJ-UHFFFAOYSA-N 7-methoxy-6-nitro-2,3,4,5-tetrahydro-1h-1-benzazepine Chemical compound N1CCCCC2=C([N+]([O-])=O)C(OC)=CC=C21 NYHWCJTZGDKRIJ-UHFFFAOYSA-N 0.000 claims 1
- WGZBAEWYTXWWCV-UHFFFAOYSA-N 7-methoxy-8-nitro-2,3,4,5-tetrahydro-1h-1-benzazepine Chemical compound C1CCCNC2=C1C=C(OC)C([N+]([O-])=O)=C2 WGZBAEWYTXWWCV-UHFFFAOYSA-N 0.000 claims 1
- QXOPSEFXKXDFCS-UHFFFAOYSA-N 8-bromo-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepine Chemical compound C1CCCNC2=C1C=C(OC)C(Br)=C2 QXOPSEFXKXDFCS-UHFFFAOYSA-N 0.000 claims 1
- 101100295738 Gallus gallus COR3 gene Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 239000000203 mixture Substances 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000003756 stirring Methods 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 235000011121 sodium hydroxide Nutrition 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 7
- -1 methylsulphonyl Chemical group 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
- 229910052681 coesite Inorganic materials 0.000 description 6
- 229910052906 cristobalite Inorganic materials 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000003478 serotonin 5-HT2 receptor agonist Substances 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 235000012239 silicon dioxide Nutrition 0.000 description 6
- 229910052682 stishovite Inorganic materials 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229910052905 tridymite Inorganic materials 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 229940083608 sodium hydroxide Drugs 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000004031 partial agonist Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical group N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 229940072107 ascorbate Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 210000001841 basilar artery Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 3
- 229960001289 prazosin Drugs 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- BQZZRUBMHMBJPH-UHFFFAOYSA-N 1-(7-hydroxy-2,3,4,5-tetrahydro-1h-1-benzazepin-8-yl)ethanone;hydrochloride Chemical compound Cl.N1CCCCC2=C1C=C(C(=O)C)C(O)=C2 BQZZRUBMHMBJPH-UHFFFAOYSA-N 0.000 description 2
- MXQZWBASVYAGPH-UHFFFAOYSA-N 1-(7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone Chemical compound N1CC(C(C)=O)CCC2=CC(OC)=CC=C21 MXQZWBASVYAGPH-UHFFFAOYSA-N 0.000 description 2
- SRFHAOKZRXCDNB-UHFFFAOYSA-N 1-(8-bromo-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone Chemical compound C1CC(C(C)=O)CNC2=C1C=C(OC)C(Br)=C2 SRFHAOKZRXCDNB-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- GZBOOGQTVWTMSO-UHFFFAOYSA-N 7-methoxy-6-nitro-2,3,4,5-tetrahydro-1h-1-benzazepine;hydrochloride Chemical compound Cl.N1CCCCC2=C([N+]([O-])=O)C(OC)=CC=C21 GZBOOGQTVWTMSO-UHFFFAOYSA-N 0.000 description 2
- TVHCFCUDQLGIEU-UHFFFAOYSA-N 7-methoxy-8-nitro-2,3,4,5-tetrahydro-1h-1-benzazepine;hydrochloride Chemical compound Cl.C1CCCNC2=C1C=C(OC)C([N+]([O-])=O)=C2 TVHCFCUDQLGIEU-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- XCGSFFUVFURLIX-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1 XCGSFFUVFURLIX-VFGNJEKYSA-N 0.000 description 2
- 229960004943 ergotamine Drugs 0.000 description 2
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 2
- 229960005417 ketanserin Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000006396 nitration reaction Methods 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- YUMSLMZQFJSQFJ-UHFFFAOYSA-N 1-(6-bromo-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone Chemical compound N1CC(C(C)=O)CCC2=C(Br)C(OC)=CC=C21 YUMSLMZQFJSQFJ-UHFFFAOYSA-N 0.000 description 1
- XFOFZIYLHJDUHC-UHFFFAOYSA-N 1-(7-hydroxy-8-methylsulfinyl-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone Chemical compound N1CC(C(=O)C)CCC2=CC(O)=C(S(C)=O)C=C21 XFOFZIYLHJDUHC-UHFFFAOYSA-N 0.000 description 1
- ZMUOBKSIFIWSOH-UHFFFAOYSA-N 1-(7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone;hydrochloride Chemical compound Cl.N1CC(C(C)=O)CCC2=CC(OC)=CC=C21 ZMUOBKSIFIWSOH-UHFFFAOYSA-N 0.000 description 1
- GLXVADCXADCGTO-UHFFFAOYSA-N 1-(7-methoxy-6-nitro-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone Chemical compound N1CC(C(C)=O)CCC2=C([N+]([O-])=O)C(OC)=CC=C21 GLXVADCXADCGTO-UHFFFAOYSA-N 0.000 description 1
- KZYXNJBAWOGVHE-UHFFFAOYSA-N 1-(7-methoxy-6-nitro-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone;hydrochloride Chemical compound Cl.N1CC(C(C)=O)CCC2=C([N+]([O-])=O)C(OC)=CC=C21 KZYXNJBAWOGVHE-UHFFFAOYSA-N 0.000 description 1
- DFDHTCMRNRNGQM-UHFFFAOYSA-N 1-(7-methoxy-8-methylsulfinyl-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone Chemical compound C1CC(C(C)=O)CNC2=C1C=C(OC)C(S(C)=O)=C2 DFDHTCMRNRNGQM-UHFFFAOYSA-N 0.000 description 1
- RFVBRODPPJECBI-UHFFFAOYSA-N 1-(7-methoxy-8-nitro-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone Chemical compound C1CC(C(C)=O)CNC2=C1C=C(OC)C([N+]([O-])=O)=C2 RFVBRODPPJECBI-UHFFFAOYSA-N 0.000 description 1
- QRAOLIUHDOZBGF-UHFFFAOYSA-N 1-(7-methoxy-8-sulfanyl-2,3,4,5-tetrahydro-1h-1-benzazepin-3-yl)ethanone Chemical compound C1CC(C(C)=O)CNC2=C1C=C(OC)C(S)=C2 QRAOLIUHDOZBGF-UHFFFAOYSA-N 0.000 description 1
- MGRUKQRWLMXJDP-UHFFFAOYSA-N 1-methylsulfonyl-2,3,4,5-tetrahydro-1-benzazepine Chemical compound CS(=O)(=O)N1CCCCC2=CC=CC=C12 MGRUKQRWLMXJDP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- AESTUMJPPFCEJQ-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1-benzazepine;hydrochloride Chemical compound Cl.N1CCCCC2=CC=CC=C21 AESTUMJPPFCEJQ-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- TZDYNMUCJXCUGW-UHFFFAOYSA-N 3-acetyl-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepine-8-sulfonyl chloride Chemical compound C1CC(C(C)=O)CNC2=C1C=C(OC)C(S(Cl)(=O)=O)=C2 TZDYNMUCJXCUGW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XXJBFTZRNFDGDV-UHFFFAOYSA-N 6-bromo-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepine;hydrochloride Chemical compound Cl.N1CCCCC2=C(Br)C(OC)=CC=C21 XXJBFTZRNFDGDV-UHFFFAOYSA-N 0.000 description 1
- BYXDLVCDCXGHOK-UHFFFAOYSA-N 7-bromo-8-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepine;hydrochloride Chemical compound Cl.N1CCCCC2=C1C=C(OC)C(Br)=C2 BYXDLVCDCXGHOK-UHFFFAOYSA-N 0.000 description 1
- HOBVGWUEGWDWTB-UHFFFAOYSA-N 7-hydroxy-2,3,4,5-tetrahydro-1h-1-benzazepine-8-sulfonamide Chemical compound N1CCCCC2=C1C=C(S(=O)(=O)N)C(O)=C2 HOBVGWUEGWDWTB-UHFFFAOYSA-N 0.000 description 1
- NCEAVILOSZFVPM-UHFFFAOYSA-N 7-methoxy-8-methylsulfinyl-2,3,4,5-tetrahydro-1h-1-benzazepine;oxalic acid Chemical compound OC(=O)C(O)=O.C1CCCNC2=C1C=C(OC)C(S(C)=O)=C2 NCEAVILOSZFVPM-UHFFFAOYSA-N 0.000 description 1
- HZQZSHLPFAEMLD-UHFFFAOYSA-N 7-methylsulfonyl-2,3,4,5-tetrahydro-1h-3-benzazepin-8-ol Chemical compound C1CNCCC2=C1C=C(S(=O)(=O)C)C(O)=C2 HZQZSHLPFAEMLD-UHFFFAOYSA-N 0.000 description 1
- NHVNVQPRDOOVGK-UHFFFAOYSA-N 8-bromo-2,3,4,5-tetrahydro-1h-1-benzazepin-7-ol Chemical compound C1CCCNC2=C1C=C(O)C(Br)=C2 NHVNVQPRDOOVGK-UHFFFAOYSA-N 0.000 description 1
- TVYXETGKJAEWIC-UHFFFAOYSA-N 8-bromo-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepine;hydrochloride Chemical compound Cl.C1CCCNC2=C1C=C(OC)C(Br)=C2 TVYXETGKJAEWIC-UHFFFAOYSA-N 0.000 description 1
- XBLPBGVEJSJYHB-UHFFFAOYSA-N 8-nitro-2,3,4,5-tetrahydro-1h-1-benzazepin-7-ol;hydrochloride Chemical compound Cl.C1CCCNC2=C1C=C(O)C([N+]([O-])=O)=C2 XBLPBGVEJSJYHB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013753 Drug withdrawal headache Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000982822 Ficus obtusifolia Species 0.000 description 1
- 229910001111 Fine metal Inorganic materials 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 206010056091 Varices oesophageal Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- LUZRJRNZXALNLM-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 LUZRJRNZXALNLM-JGRZULCMSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- 210000001363 mesenteric artery superior Anatomy 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229960001186 methysergide Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 210000001994 temporal artery Anatomy 0.000 description 1
- UWPPADMWQVNQFC-UHFFFAOYSA-J tetrachlorostannane;hydrochloride Chemical compound Cl.Cl[Sn](Cl)(Cl)Cl UWPPADMWQVNQFC-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000008320 venous blood flow Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9113379.3 | 1991-06-21 | ||
| GB919113379A GB9113379D0 (en) | 1991-06-21 | 1991-06-21 | Medicaments |
| GB919113377A GB9113377D0 (en) | 1991-06-21 | 1991-06-21 | Medicaments |
| GB9113377.7 | 1991-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2110575A1 true CA2110575A1 (fr) | 1993-01-07 |
Family
ID=26299102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002110575A Abandoned CA2110575A1 (fr) | 1991-06-21 | 1992-06-17 | Utilisation de derives de tetrahydrobenzazepine dans le traitement de l'hypertension et de la migraine spleniques |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0589973A1 (fr) |
| JP (1) | JPH06508352A (fr) |
| KR (1) | KR940701258A (fr) |
| AU (1) | AU1927992A (fr) |
| CA (1) | CA2110575A1 (fr) |
| IE (1) | IE921990A1 (fr) |
| MX (1) | MX9203012A (fr) |
| PT (1) | PT100602A (fr) |
| WO (1) | WO1993000094A2 (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9211277D0 (en) | 1992-05-28 | 1992-07-15 | Glaxo Group Inc | Pharmaceutical compositions |
| BR9708145A (pt) * | 1996-03-25 | 1999-07-27 | Lilly Co Eli | Processo para tratamento de dor de enxaqueca |
| US7189753B1 (en) | 1997-11-06 | 2007-03-13 | Cady Roger K | Preemptive prophylaxis of migraine |
| JPWO2002074746A1 (ja) * | 2001-03-16 | 2004-07-08 | 山之内製薬株式会社 | ベンゾアゼピン誘導体 |
| US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| PT1572215E (pt) | 2002-12-20 | 2009-12-09 | Glaxo Group Ltd | Derivados de benzo[d]azepina para o tratamento de perturbações neurológicas |
| US8367657B2 (en) | 2003-06-17 | 2013-02-05 | Arena Pharmaceuticals, Inc. | Processes for preparing 3-benzazepines |
| CN1805938B (zh) | 2003-06-17 | 2010-06-16 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
| TW200510324A (en) * | 2003-08-11 | 2005-03-16 | Lilly Co Eli | 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist |
| EP2149562A1 (fr) | 2004-12-21 | 2010-02-03 | Arena Pharmaceuticals, Inc. | Méthode pour préparer l'hemihydrate de l'hydrochlorure de (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| NZ589951A (en) | 2004-12-23 | 2012-11-30 | Arena Pharm Inc | 5HT2C receptor modulator compositions and methods of use |
| CA2646044A1 (fr) | 2006-04-03 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Procedes de preparation de 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine et produits intermediaires associes |
| EP2099743B1 (fr) | 2006-12-05 | 2014-08-27 | Arena Pharmaceuticals, Inc. | Procédés de préparation de (r)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1h-3-benzazépine et intermédiaires de celle-ci |
| US8822727B2 (en) | 2008-03-04 | 2014-09-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| WO2010148207A2 (fr) | 2009-06-18 | 2010-12-23 | Arena Pharmaceuticals, Inc. | Procédés pour la préparation d'agonistes du récepteur 5-ht2c |
| WO2011153206A1 (fr) | 2010-06-02 | 2011-12-08 | Arena Pharmaceuticals, Inc. | Procédés pour la préparation d'agonistes du récepteur 5-ht2c |
| KR20130138768A (ko) * | 2010-09-01 | 2013-12-19 | 아레나 파마슈티칼스, 인크. | 5-ｈｔ2ｃ 아고니스트의 신속-용해성 투여 형태 |
| JP2013539470A (ja) * | 2010-09-01 | 2013-10-24 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ロルカセリンと光学活性な酸との塩 |
| KR20180118801A (ko) | 2010-09-01 | 2018-10-31 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태 |
| EA201390335A1 (ru) | 2010-09-01 | 2013-09-30 | Арена Фармасьютикалз, Инк. | Введение лоркасерина индивидуумам с почечной недостаточностью |
| KR20130101524A (ko) | 2010-09-01 | 2013-09-13 | 아레나 파마슈티칼스, 인크. | 5-ｈｔ2ｃ 아고니스트의 비-흡습성 염 |
| RU2674670C1 (ru) | 2012-10-09 | 2018-12-12 | Арена Фармасьютикалз, Инк. | Способ коррекции массы тела |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4659706A (en) * | 1985-12-20 | 1987-04-21 | Smithkline Beckman Corporation | Sulfinyl and sulfonyl substituted 3-benzazepines |
-
1992
- 1992-06-17 WO PCT/GB1992/001083 patent/WO1993000094A2/fr not_active Ceased
- 1992-06-17 AU AU19279/92A patent/AU1927992A/en not_active Abandoned
- 1992-06-17 EP EP92912293A patent/EP0589973A1/fr not_active Withdrawn
- 1992-06-17 KR KR1019930703940A patent/KR940701258A/ko not_active Withdrawn
- 1992-06-17 JP JP4511087A patent/JPH06508352A/ja active Pending
- 1992-06-17 PT PT100602A patent/PT100602A/pt not_active Application Discontinuation
- 1992-06-17 CA CA002110575A patent/CA2110575A1/fr not_active Abandoned
- 1992-06-19 MX MX9203012A patent/MX9203012A/es unknown
- 1992-07-01 IE IE199092A patent/IE921990A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU1927992A (en) | 1993-01-25 |
| WO1993000094A2 (fr) | 1993-01-07 |
| KR940701258A (ko) | 1994-05-28 |
| WO1993000094A3 (fr) | 1993-03-04 |
| PT100602A (pt) | 1993-09-30 |
| MX9203012A (es) | 1993-07-01 |
| JPH06508352A (ja) | 1994-09-22 |
| IE921990A1 (en) | 1992-12-30 |
| EP0589973A1 (fr) | 1994-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0589973A1 (fr) | Medicaments | |
| CN105646389B (zh) | 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途 | |
| WO2022121813A1 (fr) | Inhibiteur de sos1, composition pharmaceutique le comprenant et son utilisation | |
| CN105481789A (zh) | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法 | |
| AU2014323822B2 (en) | Immune adjustment compound, use thereof and pharmaceutical composition comprising same | |
| WO1999020620A1 (fr) | Derive d'isoquinoleine et medicament | |
| WO2022105852A1 (fr) | Dérivé de triazine dione, son procédé de préparation et son application en médecine | |
| TW201412737A (zh) | 吡唑並［３，４－ｃ］吡啶類衍生物、其製備方法及其在醫藥上的應用 | |
| JP5575979B2 (ja) | シアノ基を含有するチエノピリジンエステル誘導体、その調製方法、使用および組成物 | |
| WO2000028993A1 (fr) | Ligands de serotonine en tant que composes favorisant l'erection | |
| CN114149423A (zh) | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| CN114539229A (zh) | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| WO2016000568A1 (fr) | Composé pour le traitement de la goutte | |
| PT644878E (pt) | Compostos 2,5-dio-2,5-di-hidro-1h-benzo¬b|azepina como antagonistas do receptor nmda | |
| JPH05213888A (ja) | 治療剤 | |
| BR112019026945A2 (pt) | derivado de indol-formamida, método de preparação para ele e seu uso em medicina | |
| JP3853389B2 (ja) | 新規の３−フェニルスルホニル−３，７−ジアザビシクロ［３，３，１］ノナン−化合物、その製法及び抗不整脈剤 | |
| EP4174068A1 (fr) | Nouveau composé et composition pharmaceutique le comprenant pour prévenir ou traiter un cancer résistant | |
| KR100339115B1 (ko) | 결정성3-(4-헥실옥시-1,2,5-티아디아졸-3-일)-1,2,5,6-테트라하이드로-1-메틸피리딘(+)l-하이드로겐타르트레이트,이의제조방법및이를포함하는약제학적조성물 | |
| CA3075324A1 (fr) | Derive d'indole-formamide substitue par un atome de deuterium, son procede de preparation et ses applications medicales | |
| US4897423A (en) | Dinitrobenzenesulfonamides | |
| JP5180219B2 (ja) | 新規なモルヒネ誘導体 | |
| WO2022161462A1 (fr) | Dérivé de morpholine, composition pharmaceutique et leur utilisation | |
| US6071968A (en) | Phenylenediamine derivative radical scavenger, brain-infarction depressant, and brain-edema depressant | |
| US20160039820A1 (en) | Pyridoindolobenz[b,e]azepine derivatives and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |